Washington DC
Regenxbio reports $40.7 million Q3 loss, beats expectations in Rockville
Rockville-based Regenxbio posted a $40.7 million loss in Q3, surpassing Wall Street loss estimates but missing revenue forecasts.
Photo: Sean McCue / CC BY-SA 2.5, via Wikimedia Commons
Regenxbio Inc., a biotechnology company based in Rockville, Maryland, reported a third-quarter loss of $40.7 million, according to WTOP's report on November 5. This amounted to a loss of 62 cents per share for the period.
Despite the loss, Regenxbio's results exceeded Wall Street expectations. Analysts surveyed by Zacks Investment Research had forecast a larger loss of $1.35 per share on average.
The company posted revenue of $9.2 million for the quarter, which fell short of the expected $9.6 million revenue estimated by analysts.
Sources
We read public reporting and official data, confirm what we can, and write our own story. See something wrong? Request a correction.
Comments
No comments yet.
Sign in to comment